A Dark Vector Cognition product
10-K/A comparison

Bio-Techne (TECH) 10-K/A risk factor changes: FY2026 vs FY2019

The 2026-06-30 10-K/A against the 2019-06-30 one, compared heading by heading and sentence by sentence. One of these filings carries no fiscal year tag, so its year is the calendar year of the period end.

All filing items27 rewritten871 added1,301 removed17 unchanged

Read the changes

Bio-Techne Form 10-K/A, every itemFY2026, filed 28 October 2026, against FY2019, filed 9 October 2019FY2026 on sec.govFY2019 on sec.govRead this filing

Summary

counted, not written

Sentences by item

7 items, with every count and a link to each item that changed

Underlined words on a shaded ground are new in FY2026; struck-through words were in FY2019. Sentences that are wholly new or wholly gone are labelled rather than marked.

Cover and table of contents

27 rewritten, 755 added, 13 removed, 17 unchanged

Read the full itemFY2026 item · filed October 28, 2026FY2019 item · filed October 9, 2019

Rewritten

[removed: UNITED STATES][added: UNITED STATES]

Rewritten

[removed: SECURITIES] [added: SECURITIES] AND EXCHANGE [removed: COMMISSION][added: COMMISSION]

Rewritten

[removed: Washington,] [added: Washington,] DC [removed: 20549][added: 20549]

Rewritten

[removed: FORM 10-K][added: FORM 10-K/A]

Rewritten

[removed: Amendment] [added: (Amendment] No. [removed: 1][added: 1)]

Rewritten

| ☒ | [removed: ANNUAL] [added: ANNUAL] REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF [removed: 1934] [added: 1934] |

Rewritten

[removed: For] [added: For] the fiscal year ended June 30, [removed: 2019, or][added: 2026, or]

Rewritten

| ☐ | [removed: TRANSITION] [added: TRANSITION] REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF [removed: 1934] [added: 1934] |

Rewritten

[removed: For] [added: For] the transition [removed: period][added: period]

Rewritten

[removed: Commission] [added: Commission] file number [removed: 0-17272][added: 0-17272]

Rewritten

[removed: BIO-TECHNE CORPORATION][added: BIO-TECHNE CORPORATION]

Rewritten

[removed: (Exact] [added: (Exact] name of registrant as specified in its [removed: charter)][added: charter)]

Rewritten

| [removed: Minnesota] [added: Minnesota] | | [removed: 41-1427402] [added: 41-1427402] |

Rewritten

| [removed: (State] [added: (State] or other jurisdiction [removed: of incorporation] [added: of incorporation] or [removed: organization)] [added: organization)] | | [removed: (I.R.S. Employer Identification No.)] [added: (I.R.S. Employer Identification No.)] |

Rewritten

| [removed: 614] [added: 614] McKinley Place [removed: N.E. Minneapolis,] [added: N.E. Minneapolis,] MN [removed: 55413] [added: 55413] | | [removed: (612) 379-8854] [added: (612) 379-8854] |

Rewritten

| [removed: (Address] [added: (Address] of principal executive offices) (Zip [removed: Code)] [added: Code)] | | [removed: (Registrant's] [added: (Registrant’s] telephone number, including area [removed: code)] [added: code)] |

Rewritten

[removed: Securities] [added: Securities] registered pursuant to Section 12(b) of the [removed: Act:][added: Act:]

Rewritten

| [removed: Title] [added: Title] of each [removed: class] [added: class] | [removed: Trading Symbol(s)] [added: Trading Symbol(s)] | [removed: Name] [added: Name] of each exchange on which [removed: registered] [added: registered] |

Rewritten

[removed: Securities] [added: Securities] registered pursuant to Section 12(g) of the Act: [removed: None][added: None]

Rewritten

| Large accelerated filer | [removed: |] ☒ | [removed: |] Accelerated filer | [removed: |] ☐ |

Rewritten

| Non-accelerated filer | [removed: |] ☐ | [removed: |] Smaller reporting company | [removed: |] ☐ |

Rewritten

| | | [removed: | |] Emerging growth company | [removed: |] ☐ |

Rewritten

As of December 31, [removed: 2018] [added: 2025,] the aggregate market value of the Common Stock held by non-affiliates of the Registrant was [removed: $5.5] [added: $9.1] billion based upon the closing sale price as reported on The Nasdaq Stock Market [removed: ($144.72] [added: ($58.81] per share).

Rewritten

As of [removed: August 26, 2019, 38,063,504] [added: October 9, 2026, 157,055,564] shares of the Company’s Common Stock ($0.01 par value) were outstanding.

Rewritten

[removed: EXPLANATORY NOTE][added: EXPLANATORY NOTE]

Rewritten

[removed: TABLE] [added: TABLE] OF [removed: CONTENTS][added: CONTENTS]

Rewritten

| [removed: Item] [added: [ITEM] 15. [removed: | [Exhibits, Financial Statement Schedules](#item15)] [added: EXHIBITS, FINANCIAL STATEMENT SCHEDULES](#ITEM15.)] | [removed: 40] [added: 45] |

New in FY2026

Indicate by check mark whether the registrant has filed a report on and attestation to its management’s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report.

New in FY2026

If securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the registrant included in the filing reflect the correction of an error to previously issued financial statements.

New in FY2026

Indicate by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-based compensation received by any of the registrant’s executive officers during the relevant recovery period pursuant to §240.10D-1(b).

New in FY2026

DOCUMENTS INCORPORATED BY REFERENCE

New in FY2026

None.

New in FY2026

This Amendment No. 1 on Form 10-K/A (the “Form 10-K/A”) to the Annual Report on Form 10-K of Bio-Techne Corporation (the “Company”) for the fiscal year ended June 30, 2026, filed with the Securities and Exchange Commission (the “SEC”) on August 24, 2026 (the “Original Report”), is being filed solely for the purpose of including the information required by Part III of Form 10-K that the Company did not include in the Original Report in reliance on General Instruction G(3) to Form 10-K, which permits this information to be incorporated by reference from a registrant’s definitive proxy statement if the proxy statement is filed within 120 days after fiscal year-end.

New in FY2026

We are filing this Form 10-K/A to include Part III information in our Form 10-K because we do not intend to file a definitive proxy statement for an annual meeting of shareholders containing such information within 120 days after the end of our fiscal year ended June 30, 2026.

New in FY2026

The reference on the cover page of the Original Report to such incorporation by reference has been deleted and the number of shares of Common Stock outstanding has been updated.

New in FY2026

This Form 10-K/A amends and restates in their entirety Items 10 through 14 of Part III of the Original Report.

New in FY2026

Capitalized terms not otherwise defined in Part III of this Form 10-K/A shall have the same meanings assigned to those terms in Parts I and II of the Original Report.

New in FY2026

In addition, in connection with the filing of this Form 10-K/A and pursuant to the rules of the SEC, we are including in this Form 10-K/A new certifications of our principal executive officer and principal financial officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002, which are filed as Exhibits 31.3 and 31.4 to this Form 10-K/A.

New in FY2026

Item 15 of Part IV of the Original Report is amended solely to add these certifications to the exhibit index, and the exhibit index and the exhibits filed with the Original Report are not otherwise amended or restated.

New in FY2026

Because no financial statements are included in this Form 10-K/A and this Form 10-K/A does not contain or amend any disclosure with respect to Items 307 and 308 of Regulation S-K, paragraphs 3, 4, and 5 of the certifications have been omitted.

New in FY2026

Because no financial statements are contained in this Form 10-K/A, we are not including certifications pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

New in FY2026

Except as described above, this Form 10-K/A does not modify or update the disclosures in, or any exhibits to, the Original Report.

New in FY2026

Furthermore, this Form 10-K/A does not change any previously reported financial results, nor does it reflect any events which occurred subsequent to the filing of the Original Report.

New in FY2026

Information not affected by this Form 10-K/A remains unchanged and reflects the disclosures made at the time the Original Report was filed.

New in FY2026

Unless otherwise specified or indicated by the context, “Bio-Techne,” the “Company,” “we,” “us” and “our” refer to Bio-Techne, its divisions and subsidiaries.

New in FY2026

| [PART III](#PARTIII) | 5 |

New in FY2026

| [ITEM 10. DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE](#ITEM10.) | 5 |

New in FY2026

| [ITEM 11. EXECUTIVE COMPENSATION](#ITEM11.) | 13 |

New in FY2026

| [ITEM 12. SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED SHAREHOLDER MATTERS](#ITEM12.) | 39 |

New in FY2026

| [ITEM 13. CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS, AND DIRECTOR INDEPENDENCE](#ITEM13.) | 43 |

New in FY2026

| [ITEM 14. PRINCIPAL ACCOUNTANT FEES AND SERVICES](#ITEM14.) | 44 |

New in FY2026

| [PART IV](#PARTIV) | 45 |

New in FY2026

[*Table of Contents*](#TABLEOFCONTENTS)

New in FY2026

PART III

New in FY2026

| ITEM 10. | DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE |

New in FY2026

EXECUTIVE OFFICERS

New in FY2026

Information regarding our executive officers is set forth under the “Executive Officers of the Registrant” caption in Part I, Item 1 of the Original Report, which is hereby incorporated by reference.

New in FY2026

DIRECTORS

New in FY2026

The following sets forth information concerning the directors serving on the Board of Directors (the “Board”) of the Company.

New in FY2026

Director Qualifications and Experience

New in FY2026

[*Table of Contents*](#TABLEOFCONTENTS)

New in FY2026

| | Skills, Qualifications, and Background | | ![graphic](https://www.sec.gov/Archives/edgar/data/842023/000114036126041062/image37.jpg) | ![graphic](https://www.sec.gov/Archives/edgar/data/842023/000114036126041062/image36.jpg) | ![graphic](https://www.sec.gov/Archives/edgar/data/842023/000114036126041062/image35.jpg) | ![graphic](https://www.sec.gov/Archives/edgar/data/842023/000114036126041062/image33.jpg) | ![graphic](https://www.sec.gov/Archives/edgar/data/842023/000114036126041062/image34.jpg) | ![graphic](https://www.sec.gov/Archives/edgar/data/842023/000114036126041062/image38.jpg) | ![graphic](https://www.sec.gov/Archives/edgar/data/842023/000114036126041062/image39.jpg) | ![graphic](https://www.sec.gov/Archives/edgar/data/842023/000114036126041062/image40.jpg) | ![graphic](https://www.sec.gov/Archives/edgar/data/842023/000114036126041062/image41.jpg) | |

New in FY2026

| | ![graphic](https://www.sec.gov/Archives/edgar/data/842023/000114036126041062/image9.jpg) | Executive/Strategic Leadership | ![graphic](https://www.sec.gov/Archives/edgar/data/842023/000114036126041062/image10.jpg) | ![graphic](https://www.sec.gov/Archives/edgar/data/842023/000114036126041062/image10.jpg) | | ![graphic](https://www.sec.gov/Archives/edgar/data/842023/000114036126041062/image10.jpg) | ![graphic](https://www.sec.gov/Archives/edgar/data/842023/000114036126041062/image10.jpg) | ![graphic](https://www.sec.gov/Archives/edgar/data/842023/000114036126041062/image10.jpg) | ![graphic](https://www.sec.gov/Archives/edgar/data/842023/000114036126041062/image10.jpg) | ![graphic](https://www.sec.gov/Archives/edgar/data/842023/000114036126041062/image10.jpg) | ![graphic](https://www.sec.gov/Archives/edgar/data/842023/000114036126041062/image10.jpg) | ![graphic](https://www.sec.gov/Archives/edgar/data/842023/000114036126041062/image11.jpg) |

New in FY2026

| | Senior-level managerial experience brings a broad perspective and knowledge to engage with management in meaningful discussions about our strategy and related strategic risks, including people management. | | | | | | | | | | | |

New in FY2026

| | ![graphic](https://www.sec.gov/Archives/edgar/data/842023/000114036126041062/image12.jpg) | Industry Background | | | ![graphic](https://www.sec.gov/Archives/edgar/data/842023/000114036126041062/image10.jpg) | ![graphic](https://www.sec.gov/Archives/edgar/data/842023/000114036126041062/image10.jpg) | ![graphic](https://www.sec.gov/Archives/edgar/data/842023/000114036126041062/image10.jpg) | ![graphic](https://www.sec.gov/Archives/edgar/data/842023/000114036126041062/image10.jpg) | ![graphic](https://www.sec.gov/Archives/edgar/data/842023/000114036126041062/image10.jpg) | ![graphic](https://www.sec.gov/Archives/edgar/data/842023/000114036126041062/image10.jpg) | ![graphic](https://www.sec.gov/Archives/edgar/data/842023/000114036126041062/image10.jpg) | ![graphic](https://www.sec.gov/Archives/edgar/data/842023/000114036126041062/image13.jpg) |

New in FY2026

| | The life science tools and diagnostics industry is complex and technology-focused, so having directors with experience in this business, either as executives or customers, is a significant advantage. | | | | | | | | | | | |

New in FY2026

| | ![graphic](https://www.sec.gov/Archives/edgar/data/842023/000114036126041062/image14.jpg) | Scientific/Technical | | | ![graphic](https://www.sec.gov/Archives/edgar/data/842023/000114036126041062/image10.jpg) | | ![graphic](https://www.sec.gov/Archives/edgar/data/842023/000114036126041062/image10.jpg) | ![graphic](https://www.sec.gov/Archives/edgar/data/842023/000114036126041062/image10.jpg) | ![graphic](https://www.sec.gov/Archives/edgar/data/842023/000114036126041062/image10.jpg) | ![graphic](https://www.sec.gov/Archives/edgar/data/842023/000114036126041062/image10.jpg) | ![graphic](https://www.sec.gov/Archives/edgar/data/842023/000114036126041062/image10.jpg) | ![graphic](https://www.sec.gov/Archives/edgar/data/842023/000114036126041062/image15.jpg) |

Dropped from FY2019

10-K/A 1 tech20190923_10ka.htm FORM 10-K/A

Dropped from FY2019

Indicate by check mark if disclosure of delinquent filers pursuant to Item 405 of Regulation S-K is not contained herein, and will not be contained, to the best of registrant’s knowledge, in definitive proxy or information statements incorporated by reference in Part III of this Form 10-K or any amendment to this Form 10-K.

Dropped from FY2019

This Amendment No. 1 on Form 10-K/A (“Amendment No. 1”) amends Bio-Techne Corporation’s (the “Company”) Annual Report on Form 10-K for the fiscal year ended June 30, 2019, as filed with the Securities and Exchange Commission (“SEC”) on August 28, 2019 (the “Original Filing”), solely to provide a revised version of KPMG LLP’s (“KPMG”) report, which corrects certain clerical items and a statement in the previously filed version that KPMG did not express an opinion on the Company’s internal controls over financial reporting, and makes a clerical correction in Item 9A to conform the name of the entity the Company acquired on June 4, 2019 to the Company’s consolidated financial statements.

Dropped from FY2019

These changes to the filed version of KPMG's report included in the original filing do not affect KPMG's unqualified opinion on the Company's consolidated financial statements or KPMG's unqualified opinion on internal control over financial reporting included in the Original Filing and this Amendment No. 1.

Dropped from FY2019

As required by Rule 12b-15 under the Securities Exchange Act of 1934, as amended, this Amendment No. 1 includes a new consent of KPMG (Exhibit 23.1), new certifications from the Company's principal executive officer (Exhibit 31.1) and principal financial officer (Exhibit 31.2) and new Section 1350 certifications (Exhibit 32.1 and 32.2) dated as of the date of filing of this Amendment No. 1.

Dropped from FY2019

This Amendment No. 1 consists solely of the preceding cover page, this explanatory note, Part II., Item 8., “Consolidated Financial Statements and Supplementary Data,” in its entirety, Part IV., Item 15., “Exhibits and Financial Statement Schedules,” in its entirety, the signature page, and the new certifications from the Company’s principal executive officer and principal financial officer.

Dropped from FY2019

Except as expressly set forth above, this Amendment does not, and does not purport to, amend, update or restate the information in any other item of the Original Filing.

Dropped from FY2019

Amendment No. 1 speaks as of the date of the Original Filing, does not reflect events that may have occurred after the date of the Original Filing and does not modify or update in any way the disclosures made in the Original Filing, except as described above.

Dropped from FY2019

Amendment No. 1 should be read in conjunction with the Original Filing and with the Company’s subsequent filings with the SEC.

Dropped from FY2019

| Item 8. | [Financial Statements and Supplementary Data](#item8) | 1 |

Dropped from FY2019

| Item 9. | [Changes in and Disagreements with Accountants on Accounting and Financial Disclosure](#item9) | 38 |

Dropped from FY2019

| Item 9A. | [Controls and Procedures](#item9a) | 38 |

Dropped from FY2019

| | [SIGNATURES](#signatures) | 42 |

An excerpt. Shown here: all 27 rewritten, 40 of 755 added and all 13 removed. The counts are complete. For every sentence, read Cover and table of contents in the FY2026 filing and the FY2019 filing.

Item 12. SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED SHAREHOLDER MATTERS

0 rewritten, 65 added, 0 removed, 0 unchanged

New section this year

Read the full itemFY2026 item · filed October 28, 2026

New in FY2026

EQUITY COMPENSATION PLAN INFORMATION

New in FY2026

We currently award stock-based compensation, including stock options and restricted stock units, under the 2020 Equity Incentive Plan.

New in FY2026

The following table presents information about common stock authorized for issuance under that plan as of June 30, 2026:

New in FY2026

| | Plan Category | | Number of Securities to be Issued Upon Exercise of Outstanding Options (# in 000’s) | | | | Weighted Avg. Exercise Price of Outstanding Options ($) | | | | Number of Securities Remaining Available for Future Issuance Under Equity Compensation Plans (Excluding Securities Reflected in Column (A)) (# in 000’s) | | |

New in FY2026

| | | | (A) | | | | (B) | | | | (C) | | |

New in FY2026

| | Equity compensation plans approved by shareholders | | | 6,991 | | | $ | 73.47 | | | | 5,876 | |

New in FY2026

| | Equity compensation plans not approved by shareholders | | | \- | | | | N/A | | | | \- | |

New in FY2026

| | Total | | | 6,991 | | | | 73.47 | | | | 5,876 | |

New in FY2026

As of October 9, 2026, there were 5,242,909 shares available for future grants under the 2020 Equity Incentive Plan, and the closing price per share of our common stock was $72.46 as reported on The Nasdaq Global Select Market.

New in FY2026

[*Table of Contents*](#TABLEOFCONTENTS)

New in FY2026

Principal Shareholders

New in FY2026

The following table provides information concerning the only persons known to the Company to be the beneficial owners of more than 5% of the Company’s outstanding common stock as of October 9, 2026.

New in FY2026

| | Name and Address of Beneficial Owner | | Amount and Nature of Shares Beneficially Owned | | | | | Percent of Class | | |

New in FY2026

| | Vanguard Capital Management | | | | | | | | | |

New in FY2026

| | | | | 11,559,571 | (1) | | | | 7.4 | % |

New in FY2026

| | BlackRock, Inc. | | | | | | | | | |

New in FY2026

| | | | | 11,011,556 | (2) | | | | 7.0 | % |

New in FY2026

| | FMR LLC | | | | | | | | | |

New in FY2026

| | | | | 12,754,784 | (3) | | | | 8.1 | % |

New in FY2026

| (1) | Based solely on information contained in a Schedule 13G, filed with the SEC on April 29, 2026, by Vanguard Capital Management (“VCM”), in which VCM reported that, as of March 31, 2026, it had sole voting power as to 1,379,862 shares of Bio-Techne Common Stock and sole dispositive power as to 11,559,571 shares of Bio-Techne Common Stock. The address of VCM is 100 Vanguard Boulevard, Malvern, Pennsylvania 19355. |

New in FY2026

| (2) | Based solely on information contained in a Schedule 13G/A, filed with the SEC on July 16, 2025, by BlackRock, Inc. (“BlackRock”), in which BlackRock reported that, as of June 30, 2025, it had sole voting power as to 10,333,812 shares of Bio-Techne Common Stock and sole dispositive power as to 11,011,556 shares of Bio-Techne Common Stock. The address of BlackRock is 50 Hudson Yards, New York, New York 10001. |

New in FY2026

| (3) | Based solely on information contained in a Schedule 13G/A, filed with the SEC on August 6, 2026, by FMR LLC (“FMR”), in which FMR reported that, as of June 30, 2026, it had sole voting power as to 12,715,889.05 shares of Bio-Techne Common Stock and sole dispositive power as to 12,754,783.64 shares of Bio-Techne Common Stock. The address of FMR is 245 Summer Street, Boston, Massachusetts 02210. |

New in FY2026

[*Table of Contents*](#TABLEOFCONTENTS)

New in FY2026

Management Shareholdings

New in FY2026

The following table sets forth the number of shares of the Company’s common stock beneficially owned as of October 9, 2026, by each named executive officer, by each director, and by all directors and current executive officers as a group.

New in FY2026

Each individually beneficially owns less than one percent of total shares outstanding, which includes shares subject to options such individual may exercise.

New in FY2026

As a group, executive officers and directors beneficially own 1.3% of total shares outstanding.

New in FY2026

| | Name of Director or Executive Officer | Number of Shares Beneficially Owned(1) | | % Owned | |

New in FY2026

| | Robert V. Baumgartner | 108,265 | (2) | * | * |

New in FY2026

| | Joseph Keegan, Ph.D. | 66,792 | (3) | * | * |

New in FY2026

| | John L. Higgins | 128,635 | (4) | * | * |

New in FY2026

| | Alpna Seth, Ph.D. | 46,700 | (5) | * | * |

New in FY2026

| | Dr. Rupert Vessey, MA, BM BCh, FRCP, DPhil | 44,628 | (6) | * | * |

New in FY2026

| | Julie L. Bushman | 33,464 | (7) | * | * |

New in FY2026

| | Dr. Judith Klimovsky | 12,680 | (8) | * | * |

New in FY2026

| | Dr. Amy Herr | 20,417 | (9) | * | * |

New in FY2026

| | Kim Kelderman | 390,300 | (10) | * | * |

New in FY2026

| | James Hippel | 497,202 | (11) | * | * |

New in FY2026

| | William Geist | 111,317 | (12) | * | * |

New in FY2026

| | Shane Bohnen | 53,470 | (13) | * | * |

An excerpt. Shown here: all 0 rewritten, 40 of 65 added and all 0 removed. The counts are complete. For every sentence, read Item 12. SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED SHAREHOLDER MATTERS in the FY2026 filing.

Item 13. CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS, AND DIRECTOR INDEPENDENCE

0 rewritten, 51 added, 0 removed, 0 unchanged

New section this year

Read the full itemFY2026 item · filed October 28, 2026

New in FY2026

Related Party Transactions

New in FY2026

As provided in its charter, the Nominations and Governance Committee reviews and approves all related party transactions involving the Company’s directors and executive officers or their immediate family members to determine whether such transactions meet applicable legal requirements and are appropriately disclosed.

New in FY2026

The Company has adopted a written policy concerning the review of related party transactions, which provides that, in determining whether to approve or ratify a related party transaction, the Nominations and Governance Committee will take into account, among other factors it deems appropriate, whether the transaction is on terms no less favorable than terms generally available to an unaffiliated third party under the same or similar circumstances and the extent of the related person’s interest in the transaction.

New in FY2026

In addition, the Company’s Code of Ethics and Business Conduct requires all directors and executive officers to inform the Company’s legal counsel of any existing or proposed relationship or business transaction that could be, or might appear to be, a conflict of interest.

New in FY2026

Any reported transactions would be brought to the attention of the Nominations and Governance Committee for review and disposition.

New in FY2026

Since the beginning of the last fiscal year, there have been no related party transactions requiring disclosure under applicable rules and regulations.

New in FY2026

Board Independence

New in FY2026

Bio-Techne’s Principles of Corporate Governance provide that a majority of the Board must be independent directors under criteria established by the Board in conformity with the listing rules of the Nasdaq Stock Market.

New in FY2026

The Nominations and Governance Committee annually reviews the independence of each director, including whether there are any related party transactions.

New in FY2026

In making its most recent independence determinations, the Nominations and Governance Committee reviewed transactions and relationships between each director or any member of a director’s immediate family on one side, and the Company or any of its subsidiaries on the other side, based on information provided by the directors and from Company records and publicly available information.

New in FY2026

The Committee determined and the Board confirmed that all of the Company’s non-employee directors are independent.

New in FY2026

When Dr. Herr was appointed to the Board in fiscal year 2025, the Company noted that her partner was an employee (a non-executive officer) of a Bio-Techne subsidiary whose compensation from the Company was strictly in connection with his employment.

New in FY2026

In conjunction with Dr. Herr’s selection and formal appointment, the Board determined that this relationship, including her partner’s level and role within the Company’s subsidiary, would not undermine her ability to make decisions as a director.

New in FY2026

Accordingly, the Board determined Dr. Herr to be an independent director, and implemented additional compliance safeguards to assist Dr. Herr and her partner in maintaining her independent status.

New in FY2026

[*Table of Contents*](#TABLEOFCONTENTS)

New in FY2026

| ITEM 14. | PRINCIPAL ACCOUNTANT FEES AND SERVICES |

New in FY2026

Audit Fees

New in FY2026

The following fees were paid or payable to KPMG LLP for the fiscal years ended June 30, 2026 and 2025 (in thousands):

New in FY2026

| | | | 2025 ($) | | | | 2026 ($) | | |

New in FY2026

| | Audit Fees | | $ | 2,377 | | | $ | 2,447 | |

New in FY2026

| | Audit-Related Fees | | | 110 | | | | 110 | |

New in FY2026

| | Tax Fees | | | 254 | | | | 123 | |

New in FY2026

| | All Other Fees | | | \- | | | | \- | |

New in FY2026

“Audit Fees” are for professional services rendered and expenses incurred for the audit of the Company’s annual financial statements and review of financial statements included in our Forms 10-K and 10-Q or services that are normally provided by the accountant in connection with statutory and regulatory filings or engagements.

New in FY2026

Audit Fees also included fees incurred for the audit of the effectiveness of our internal controls over financial reporting.

New in FY2026

“Audit-Related Fees” are mainly for agreed-upon procedures (agreed-upon or expanded audit procedures related to accounting records required to respond to or comply with financial, accounting, or regulatory matters).

New in FY2026

Audit-Related Fees for fiscal year 2025 included $100,000 for ESG reporting readiness services relating to fiscal years 2024 and 2025.

New in FY2026

“Tax Fees” for fiscal year 2026 included $123,000 for domestic and international tax return preparation services and tax compliance and consulting services.

New in FY2026

“Tax Fees” for fiscal year 2025 included fees for services provided and expenses incurred in connection with (i) preparation of the Company’s tax returns in the United States, Germany, and the United Kingdom and inquiries and audits related to such returns, $118,000; and (ii) tax consulting, $136,000.

New in FY2026

[*Table of Contents*](#TABLEOFCONTENTS)

New in FY2026

Pre-Approval Policies and Procedures

New in FY2026

Pursuant to its written charter, the Audit Committee is required to pre-approve the audit and non-audit services performed by the Company’s independent registered public accounting firm.

New in FY2026

The Audit Committee may delegate to one or more of its members the authority to grant pre-approvals so long as such pre-approvals are reported to and reviewed by the full Committee at its next meeting.

New in FY2026

Annual tax services are reviewed and approved by the Audit Committee prior to the commencement of such services.

New in FY2026

All of the services rendered by KPMG LLP in fiscal years 2026 and 2025 were pre-approved by the Audit Committee.

New in FY2026

PART IV

New in FY2026

| ITEM 15. | EXHIBITS, FINANCIAL STATEMENT SCHEDULES |

New in FY2026

Item 15 of Part IV of the Original Report is hereby amended solely to add the exhibits listed below.

New in FY2026

No financial statements or financial statement schedules are filed with this Form 10-K/A, and the exhibit index included in the Original Report is not otherwise amended or restated.

New in FY2026

Exhibit Index

An excerpt. Shown here: all 0 rewritten, 40 of 51 added and all 0 removed. The counts are complete. For every sentence, read Item 13. CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS, AND DIRECTOR INDEPENDENCE in the FY2026 filing.

Item 8. FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA

0 rewritten, 0 added, 1,181 removed, 0 unchanged

Dropped this year

Read the full itemFY2019 item · filed October 9, 2019

Dropped from FY2019

CONSOLIDATED STATEMENTS OF EARNINGS AND COMPREHENSIVE INCOME

Dropped from FY2019

_Bio-Techne Corporation and Subsidiaries

Dropped from FY2019

(in thousands, except per share data)_

Dropped from FY2019

| | | __Year Ended June 30,__ | | | | | | | | | | |

Dropped from FY2019

| | | __201__9__ | | | | __201__8__ | | | | __201__7__ | | |

Dropped from FY2019

| Net sales | | $ | 714,006 | | | $ | 642,993 | | | $ | 563,003 | |

Dropped from FY2019

| Cost of sales | | | 240,515 | | | | 210,850 | | | | 188,462 | |

Dropped from FY2019

| Gross margin | | | 473,491 | | | | 432,143 | | | | 374,541 | |

Dropped from FY2019

| Operating expenses: | | | | | | | | | | | | |

Dropped from FY2019

| Selling, general and administrative | | | 264,359 | | | | 240,636 | | | | 200,443 | |

Dropped from FY2019

| Research and development | | | 62,413 | | | | 55,329 | | | | 53,514 | |

Dropped from FY2019

| Total operating expenses | | | 326,772 | | | | 295,965 | | | | 253,957 | |

Dropped from FY2019

| Operating income | | | 146,719 | | | | 136,178 | | | | 120,584 | |

Dropped from FY2019

| Other income (expense): | | | | | | | | | | | | |

Dropped from FY2019

| Interest expense | | | (21,705 | ) | | | (10,188 | ) | | | (7,361 | ) |

Dropped from FY2019

| Interest income | | | 569 | | | | 409 | | | | 304 | |

Dropped from FY2019

| Other non-operating income (expense), net | | | (13,568 | ) | | | (447 | ) | | | (1,566 | ) |

Dropped from FY2019

| Total other income (expense), net | | | (34,704 | ) | | | (10,226 | ) | | | (8,623 | ) |

Dropped from FY2019

| Earnings before income taxes | | | 112,015 | | | | 125,952 | | | | 111,961 | |

Dropped from FY2019

| Income taxes (benefit) | | | 15,943 | | | | (198) | | | | 35,875 | |

Dropped from FY2019

| Net earnings | | | 96,072 | | | | 126,150 | | | | 76,086 | |

Dropped from FY2019

| Other comprehensive income (loss): | | | | | | | | | | | | |

Dropped from FY2019

| Foreign currency translation adjustments | | | (4,487 | ) | | | (1,572 | ) | | | (3,061 | ) |

Dropped from FY2019

| Unrealized gains (losses) on derivative instruments - cash flow hedges, net of tax of $2,921 in FY19 | | | (9,537 | ) | | | \- | | | | \- | |

Dropped from FY2019

| Unrealized gains (losses) on available-for-sale investments, net of tax of $398 in FY18 and $(6,501) in FY17 | | | \- | | | | 5,693 | | | | 24,531 | |

Dropped from FY2019

| Other comprehensive income (loss) | | | (14,024 | ) | | | 4,121 | | | | 21,470 | |

Dropped from FY2019

| Comprehensive income | | $ | 82,048 | | | | 130,271 | | | $ | 97,556 | |

Dropped from FY2019

| Earnings per share: | | | | | | | | | | | | |

Dropped from FY2019

| Basic | | $ | 2.54 | | | $ | 3.36 | | | $ | 2.04 | |

Dropped from FY2019

| Diluted | | $ | 2.47 | | | $ | 3.31 | | | $ | 2.03 | |

Dropped from FY2019

| Weighted average common shares outstanding: | | | | | | | | | | | | |

Dropped from FY2019

| Basic | | | 37,781 | | | | 37,476 | | | | 37,313 | |

Dropped from FY2019

| Diluted | | | 38,892 | | | | 38,055 | | | | 37,500 | |

Dropped from FY2019

See Notes to Consolidated Financial Statements.

Dropped from FY2019

CONSOLIDATED BALANCE SHEETS

Dropped from FY2019

_Bio-Techne Corporation and Subsidiaries

Dropped from FY2019

(in thousands, except share and per share data)_

Dropped from FY2019

| | | __June 30,__ | | | | | | |

Dropped from FY2019

| | | __201__9__ | | | | __201__8__ | | |

Dropped from FY2019

| ASSETS | | | | | | | | |

An excerpt. Shown here: all 0 rewritten, all 0 added and 40 of 1,181 removed. The counts are complete. For every sentence, read Item 8. FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA in the FY2019 filing.

Item 9. CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE

0 rewritten, 0 added, 1 removed, 0 unchanged

Dropped this year

Read the full itemFY2019 item · filed October 9, 2019

Dropped from FY2019

None.

Item 9A. CONTROLS AND PROCEDURES

0 rewritten, 0 added, 29 removed, 0 unchanged

Dropped this year

Read the full itemFY2019 item · filed October 9, 2019

Dropped from FY2019

| (a) | Evaluation of Disclosure Controls and Procedures |

Dropped from FY2019

As required by Rule 13a-15(b) of the Securities Exchange Act of 1934 (the "Exchange Act"), management, with the participation of our Chief Executive Officer and Chief Financial Officer, evaluated, as of the end of the period covered by this report, the effectiveness of our disclosure controls and procedures as defined in Exchange Act Rule 13a-15(e).

Dropped from FY2019

The evaluation was based upon reports and certifications provided by a number of executives.

Dropped from FY2019

Based on that evaluation, our Chief Executive Officer and Chief Financial Officer concluded that, as of June 30, 2019, our disclosure controls and procedures were effective.

Dropped from FY2019

| (b) | Management's Annual Report on Internal Control Over Financial Reporting |

Dropped from FY2019

The Company's internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles.

Dropped from FY2019

A company's internal control over financial reporting also includes those policies and procedures that:

Dropped from FY2019

| (i) | Pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; |

Dropped from FY2019

| (ii) | Provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorizations of management and directors of the company; and |

Dropped from FY2019

| (iii) | Provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use or disposition of the company's assets that could have a material effect on the financial statements. |

Dropped from FY2019

Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements.

Dropped from FY2019

Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.

Dropped from FY2019

Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements.

Dropped from FY2019

Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.

Dropped from FY2019

A material weakness is a deficiency, or combination of deficiencies, in internal control over financial reporting such that there is a reasonable possibility that a material misstatement of the Company's annual or interim financial statements will not be prevented or detected on a timely basis.

Dropped from FY2019

We acquired QT Holding Corporation (Quad) on July 2, 2018, Exosome Diagnostics Inc. (Exosome) on August 1, 2018, and B-MoGen Biotechnologies Inc. (B-Mogen) on June 4, 2019.

Dropped from FY2019

Quad, Exosome, and B-Mogen represented approximately 17.2% of our total assets and 0.5% of our total revenues as of and for the year ended June 30, 2019.

Dropped from FY2019

We excluded internal control over financial reporting associated with Quad, Exosome, and B-Mogen from our assessment of the effectiveness of our internal control over financial reporting as of June 30, 2019.

Dropped from FY2019

Under the supervision of the Audit Committee of the Board of Directors and with the participation of our management, including our Chief Executive Officer and Chief Financial Officer, we conducted an evaluation of the effectiveness of our internal control over financial reporting using the criteria established in _Internal Control - Integrated Framework (2013)_ issued by the Committee of Sponsoring Organizations of the Treadway Commission (COSO).

Dropped from FY2019

Based on our assessment and those criteria, our Chief Executive Officer and Chief Financial Officer concluded that our internal control over financial reporting was effective as of June 30, 2019.

Dropped from FY2019

The attestation report on our internal control over financial reporting issued by KPMG LLP appears in Item 8 of this report.

Dropped from FY2019

| (c) | Changes in Internal Control Over Financial Reporting |

Dropped from FY2019

As previously announced, we acquired Quad on July 2, 2018, Exosome on August 1, 2018, and B-Mogen on June 4, 2019.

Dropped from FY2019

We have not fully evaluated any changes in internal control over financial reporting associated with these acquisitions and therefore any material changes that may result from these acquisitions have not been disclosed in this report.

Dropped from FY2019

We intend to disclose all material changes resulting from these acquisitions within or prior to the time of our first annual assessment of internal control over financial reporting that is required to include these entities.

Dropped from FY2019

We acquired Trevigen Inc (Trevigen) on September 5, 2017, Atlanta Biologicals (Atlanta) on January 2, 2018, and Eurocell Diagnostics SAS (Eurocell) on February 1, 2018, and we have implemented our internal control structure over these and incorporated its operations into our assessment of internal control over financial reporting as of June 30, 2019.

Dropped from FY2019

We have extended our oversight and monitoring processes that support internal control over financial reporting to include the operations of these entities.

Dropped from FY2019

There were no other changes in the Company's internal control over financial reporting during fiscal year 2019 that have materially affected, or are reasonably likely to materially affect, the Company's internal control over financial reporting.

Dropped from FY2019

PART IV

Item 15. EXHIBITS, FINANCIAL STATEMENT SCHEDULES

0 rewritten, 0 added, 77 removed, 0 unchanged

Dropped this year

Read the full itemFY2019 item · filed October 9, 2019

Dropped from FY2019

A.

Dropped from FY2019

(1) List of Financial Statements.

Dropped from FY2019

The following Consolidated Financial Statements are filed as part of this Annual Report on Form 10-K:

Dropped from FY2019

Consolidated Statements of Earnings and Comprehensive Income for the Years Ended June 30, 2019, 2018, and 2017

Dropped from FY2019

Consolidated Balance Sheets as of June 30, 2019 and 2018

Dropped from FY2019

Consolidated Statements of Shareholders' Equity for the Years Ended June 30, 2019, 2018, and 2017

Dropped from FY2019

Consolidated Statements of Cash Flows for the Years Ended June 30, 2019, 2018, and 2017

Dropped from FY2019

Notes to Consolidated Financial Statements for the Years Ended June 30, 2019, 2018, and 2017

Dropped from FY2019

Reports of Independent Registered Public Accounting Firm

Dropped from FY2019

A.

Dropped from FY2019

(2) Financial Statement Schedules.

Dropped from FY2019

All financial statement schedules are omitted because they are not applicable, not material or the required information is shown in the Consolidated Financial Statements or Notes thereto.

Dropped from FY2019

A.

Dropped from FY2019

(3) Exhibits.

Dropped from FY2019

EXHIBIT INDEX

Dropped from FY2019

for Form 10-K for the 2019 Fiscal Year

Dropped from FY2019

| Exhibit Number | Description |

Dropped from FY2019

| 3.1 | [Amended and Restated Articles of Incorporation of the Company--incorporated by reference to Exhibit 3.1 of the Company's Form 10-Q dated February 9, 2015*](http://www.sec.gov/Archives/edgar/data/842023/000143774915002131/ex3-1.htm) |

Dropped from FY2019

| 3.2 | [Third Amended and Restated Bylaws of the Company--incorporated by reference to Exhibit 3.1 of the Company’s Form 8-K dated February 1, 2018*](http://www.sec.gov/Archives/edgar/data/842023/000143774918001755/ex_104373.htm) |

Dropped from FY2019

| 10.1 | [Management Incentive Plan--incorporated by reference to Exhibit 10.13 of the Company's Form 10-K for the year ended June 30, 2013*](http://www.sec.gov/Archives/edgar/data/842023/000119312513351961/d545574dex1013.htm) |

Dropped from FY2019

| 10.2 | [Second Amended and Restated 2010 Equity Incentive Plan--incorporated by reference to Exhibit 10.1 of the Company's Form 8-K dated October 26, 2017*](http://www.sec.gov/Archives/edgar/data/842023/000143774917017673/ex_97613.htm) |

Dropped from FY2019

| 10.3 | [Form of Restricted Stock Award Agreement for Second Amended and Restated 2010 Equity Incentive Plan--incorporated by reference to Exhibit 10.6 of the Company's Form 8-K dated October 26, 2017*](http://www.sec.gov/Archives/edgar/data/842023/000143774917017673/ex_97618.htm) |

Dropped from FY2019

| 10.4 | [Form of Restricted Stock Unit Award Agreement for Second Amended and Restated 2010 Equity Incentive Plan attached as Exhibit 10.4 hereto](http://www.sec.gov/Archives/edgar/data/842023/000143774919017565/ex_156203.htm) |

Dropped from FY2019

| 10.5 | [Form of the Performance Unit Award Agreement for Second Amended and Restated 2010 Equity Incentive Plan attached as Exhibit 10.5 hereto](http://www.sec.gov/Archives/edgar/data/842023/000143774919017565/ex_156204.htm) |

Dropped from FY2019

| 10.6 | [Form of Incentive Stock Option Agreement for Second Amended and Restated 2010 Equity Incentive Plan--attached as Exhibit 10.6 hereto.](http://www.sec.gov/Archives/edgar/data/842023/000143774919017565/ex_156205.htm) |

Dropped from FY2019

| 10.7 | [Form of Employee Non-Qualified Stock Option Agreement for Second Amended and Restated 2010 Equity Incentive Plan--attached as Exhibit 10.7 hereto.](http://www.sec.gov/Archives/edgar/data/842023/000143774919017565/ex_156206.htm) |

Dropped from FY2019

| 10.8 | [Form of Director Non-Qualified Stock Option Agreement for Second Amended and Restated 2010 Equity Incentive Plan--incorporated by reference to Exhibit 10.2 of the Company's Form 8-K dated October 26, 2017*](http://www.sec.gov/Archives/edgar/data/842023/000143774917017673/ex_97614.htm) |

Dropped from FY2019

| 10.9 | [Employment Agreement by and between the Company and Charles Kummeth--incorporated by reference to Exhibit 10.11 of the Company's Form 10-K dated September 7, 2017*](http://www.sec.gov/Archives/edgar/data/842023/000143774917015711/ex10-11.htm) |

Dropped from FY2019

| Exhibit Number | Description |

Dropped from FY2019

| 10.10 | [Form of Employment Agreement by and between the Company and Executive Officers of the Company other than the CEO--incorporated by reference to Exhibit 10.12 of the Company's Form 10-K dated September 7, 2017*](http://www.sec.gov/Archives/edgar/data/842023/000143774917015711/ex10-12.htm) |

Dropped from FY2019

| 10.11 | [Credit Agreement by and among the Company, the Guarantors party thereto, the Lenders party thereto, and BMO Harris Bank N.A., as Administrative Agent, dated August 1, 2018--incorporated by reference to Exhibit 10.1 of the Company's Form 8-K dated August 2, 2018*](http://www.sec.gov/Archives/edgar/data/842023/000143774918014310/ex_119784.htm) |

Dropped from FY2019

| 10.12 | [Form of Indemnification Agreement entered into with each director and executive officer of the Company--incorporated by reference to Exhibit 10.1 of the Company's Form 10-Q dated February 8, 2018*](http://www.sec.gov/Archives/edgar/data/842023/000143774918001995/ex_104397.htm) |

Dropped from FY2019

| 10.13 | [Agreement and Plan of Merger by and among the Company, Aero Merger Sub Inc., Advanced Cell Diagnostics, Inc. and Fortis Advisors, LLC as the Securityholders’ Representative, dated July 6, 2016--incorporated by reference to Exhibit 2.1 of the Company's Form 8-K dated July 7, 2016*](http://www.sec.gov/Archives/edgar/data/842023/000143774916034990/ex2-1.htm) |

Dropped from FY2019

| 10.14 | [Agreement and Plan of Merger between the Company, Enzo Merger Sub. Inc., Exosome Diagnostics, Inc. and The Securityholders Representative, dated July 25, 2018--incorporated by reference to Exhibit 2.1 of the Company's Form 8-K dated June 25, 2018*](http://www.sec.gov/Archives/edgar/data/842023/000143774918012358/ex_116925.htm) |

Dropped from FY2019

| 21 | [Subsidiaries of the Company](http://www.sec.gov/Archives/edgar/data/842023/000143774919017565/ex_156245.htm) |

Dropped from FY2019

| 23 | [Consent of KPMG LLP, Independent Registered Public Accounting Firm](https://www.sec.gov/Archives/edgar/data/842023/000143774919019836/ex_159279.htm) |

Dropped from FY2019

| 31.1 | [Certification of Chief Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002](https://www.sec.gov/Archives/edgar/data/842023/000143774919019836/ex_158474.htm) |

Dropped from FY2019

| 31.2 | [Certification of Chief Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002](https://www.sec.gov/Archives/edgar/data/842023/000143774919019836/ex_158475.htm) |

Dropped from FY2019

| 32.1 | [Certification of Chief Executive Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002](https://www.sec.gov/Archives/edgar/data/842023/000143774919019836/ex_158476.htm) |

Dropped from FY2019

| 32.2 | [Certification of Chief Financial Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002](https://www.sec.gov/Archives/edgar/data/842023/000143774919019836/ex_158477.htm) |

An excerpt. Shown here: all 0 rewritten, all 0 added and 40 of 77 removed. The counts are complete. For every sentence, read Item 15. EXHIBITS, FINANCIAL STATEMENT SCHEDULES in the FY2019 filing.